SHEA FIJAL: Open Payments
NPI 1811233760 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,127 in 173 payments from 36 companies in 2025. Trend: 2023 $4,624 · 2024 $4,735 · 2025 $4,127
Food & beverage: $3,547Education: $298Long term medical supply or device loan: $283
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 21 | $657 |
| Janssen Biotech, Inc. | 20 | $434 |
| AstraZeneca Pharmaceuticals LP | 14 | $367 |
| ABBVIE INC. | 12 | $268 |
| Merck Sharp & Dohme LLC | 13 | $257 |
| Gilead Sciences, Inc. | 11 | $212 |
| Daiichi Sankyo Inc. | 5 | $168 |
| GlaxoSmithKline, LLC. | 9 | $151 |
| Novocure Inc. | 1 | $143 |
| Lilly USA, LLC | 5 | $121 |
Products named: KISQALI, KEYTRUDA, ENHERTU, Trodelvy, ERLEADA, DARZALEX, SARCLISA, Optune Lua (NovoTTF-200T).
Industry payments across MO — which companies pay providers there.
